166 related articles for article (PubMed ID: 35973038)
1. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Detection of Cancer-Testis Antigen PRAME.
Lezcano C; Müller AM; Frosina D; Hernandez E; Geronimo JA; Busam KJ; Jungbluth AA
Int J Surg Pathol; 2021 Dec; 29(8):826-835. PubMed ID: 33890816
[TBL] [Abstract][Full Text] [Related]
3. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.
Cammareri C; Beltzung F; Michal M; Vanhersecke L; Coindre JM; Velasco V; Le Loarer F; Vergier B; Perret R
Virchows Arch; 2023 Aug; 483(2):145-156. PubMed ID: 37477762
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.
Šafanda A; Kendall Bártů M; Michálková R; Stružinská I; Drozenová J; Fabián P; Hausnerová J; Laco J; Matěj R; Škapa P; Švajdler M; Špůrková Z; Méhes G; Dundr P; Němejcová K
Virchows Arch; 2023 Oct; 483(4):509-516. PubMed ID: 37610627
[TBL] [Abstract][Full Text] [Related]
5. PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis.
Hrycaj SM; Szczepanski JM; Zhao L; Siddiqui J; Thomas DG; Lucas DR; Patel RM; Harms PW; Bresler SC; Chan MP
Histopathology; 2022 Dec; 81(6):818-825. PubMed ID: 36102613
[TBL] [Abstract][Full Text] [Related]
6. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
7. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
Coppock JD; Gradecki SE; Mills AM
Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
[TBL] [Abstract][Full Text] [Related]
8. HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).
Grillini M; Ricci C; Pino V; Pedrini S; Fiorentino M; Corti B
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):14-18. PubMed ID: 34508017
[TBL] [Abstract][Full Text] [Related]
9. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
10. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
Diagn Cytopathol; 2024 Apr; ():. PubMed ID: 38558495
[TBL] [Abstract][Full Text] [Related]
11. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
12. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
13. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry for PRAME in Dermatopathology.
Lezcano C; Jungbluth AA; Busam KJ
Am J Dermatopathol; 2023 Nov; 45(11):733-747. PubMed ID: 37856737
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
17. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics.
Rawson RV; Shteinman ER; Ansar S; Vergara IA; Thompson JF; Long GV; Scolyer RA; Wilmott JS
Pathology; 2022 Dec; 54(7):863-873. PubMed ID: 35987723
[TBL] [Abstract][Full Text] [Related]
19. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
[TBL] [Abstract][Full Text] [Related]
20. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
